You are visiting a website that is not intended for your region

The page or information you have requested is intended for an audience outside the United States. By continuing to browse you confirm that you are a non-US resident requesting access to this page or information.

Switch to the US site

COVID-19 Resource Center

Healthcare professionals can find help and guidance on how to benefit from our offerings to treat your patients, as well as other practical information and advice.

Read more


Getinge Group Interim report January – March 2015


Getinge Group Interim report January – March 2015

Reporting period January – March

  • Order intake increased by 20.3% to SEK 7,192 M (5,977), and grew organically by 2.2%

  • Net sales rose by 19.2% to SEK 6,712 M (5,632), and grew organically by 1.4%

  • Profit before tax increased to SEK 146 M (-452)

  • Net profit increased to SEK 107 M (-330)

  • Earnings per share amounted to SEK 0.38 (-1.39)

  • EBITA before restructuring costs increased by 7.0% to SEK 717 M (670)

  • Operating cash flow increased by 49.3% to SEK 654 M (438)

  • Agreement concerning Consent Decree with US FDA